April 28, 2024 Asembia Specialty Pharmacy Summit 2024 2024 Asembia Conference IntegriChain was a proud silver sponsor and exhibitor at this year’s Asembia Specialty Pharmacy Summit on April 28 – May 2, 2024 at the Wynn & Encore in Las Vegas. Attendees could visit booth 1414 during the show to discuss how IntegriChain connects the commercial, financial, and operational dimensions of drug access and profitability, from strategy to operational execution. Whether you were an emerging pharmaceutical manufacturer looking to operationalize their drug commercialization strategy for their first therapy, a mid-market firm planning to enter a new therapeutic category, or a large pharma tasked with reduce their revenue leakage and Gross-to-Net (GTN) “bubble,” our team discussed solutions to optimize pricing, access and channel strategies with reliable data. Hear more about our key takeways from Asembia 2024 from Jeff Uccello,Senior VP of Data Solutions, Reena Patel, Partner at Blue Fin Group, and Dave Weiss, VP of Industry Solutions in our latest podcast. William RothSenior Vice President and Managing Partner, Consulting, Bruce PhelanPartner, Blue Fin Group Session: Commercial Considerations: Launching and Defending Against Biosimilars and Specialty Generics Description: The market for Pharmacy Benefit Specialty Generics and Biosimilars have not been the boon that the market expected. Medicaid is likely to block them because the reference product is already either free or a very low cost due to the brand taking price increases and penalties applied via the CPI-U penalty. In 2025 the incentive for Medicare Part D patients to use the generics goes away thanks to the $2000/year Out of Pocket Cap (which is the only real market that the current Specialty Generics have). And Commercial Plans don’t really want to support them because it risks massive hits to their rebate dollars. From research conducted by Blue Fin Group, Humira alone is between 25-40% of a PBMs rebates. Come hear the tailwinds and headwinds to launch and defend against.
